Engineering a cell-penetrating hyperstable antibody scFv(Ras) - An extraordinary approach to cancer therapeutics

Synth Syst Biotechnol. 2021 Oct 20;6(4):343-350. doi: 10.1016/j.synbio.2021.10.002. eCollection 2021 Dec.

Abstract

In the modern pharmaceutical industry, monoclonal antibodies are often used as therapeutic agents. However, they are restricted to cell surface antigens due to their inability to penetrate the outer cell membrane and maintain normal function in the reducing environment. Additionally, it can lead to cytotoxicity since it attacks cancerous cells by mimicking the human immune system. As an alternative, this study modifies the hyperstable single-chain fragment variable(scFv) antibody to eliminate cancer using its linear shape. The scFv(F8) antibody model was modified to recognize human Ras protein by altering residues in the antigen-binding site. Furthermore, a cell-penetrating peptide (CPP) was attached to the scFv(Ras) antibody model to allow entrance to the cell, creating CPP-scFv(Ras). Sodium dodecyl sulfate polyacrylamide gel electrophoresis(SDS-PAGE), western blotting, and the binding assay were performed to prove its effectiveness. As a result, CPP-scFv(Ras) was successfully engineered and bound to the antigen, HRas(G12V).

Keywords: Cancer therapeutics; Cell-penetrating peptide; Hyperstable; Ras protein; Single chain variable fragment antibody.